AREIT, Inc.

Disclaimer: The research and recommendation below were generated by Claude Fable. Please treat this as one input for your own research — not as the sole basis for any decision to buy or sell a stock.

Last checked: July 19, 2026
Price: 37.2500
Trading status: Normal
Recommendation: Buy (top-quality REIT for income and dividend growth)Buy
Committee call: Hold
Indices: PSEi

Analysis

AREIT - AREIT, Inc.

One-line summary: the Philippines' largest and first REIT, still growing income double digits on a steady drip of accretive Ayala Land asset infusions, trading near book value with almost no debt and a dividend that keeps rising.

Snapshot


Reviewed	July 19, 2026
Index membership	PSEi
Price at review	P37.25
Recommendation	Buy (for income and dividend-growth investors; not a short-term trading name)
Market cap	P138.4B (3.72B shares, growing as new share-for-asset swaps close)
Trailing P/E (TTM)	~13.31x
Estimated forward P/E	~13x, assuming the pending P19.5B and P21B infusions close on schedule
Dividend	P2.48/share annualized (quarterly P0.62 declared May 2026), ~6.66% yield
P/B	~1.02 (down from ~1.50 in 2021; book value has grown faster than the share price)
Debt	Near zero (D/E 0.03, Debt/EBITDA 0.35); well inside the REIT law's 35%/70% caps

Portfolio and revenue growth

Revenue and net income have compounded fast, but a large share of the growth is inorganic (new buildings added to the portfolio, not just existing tenants paying more). Revenue: P3.32B (2021), P5.07B (2022), P7.14B (2023), P10.26B (2024), P12.96B (2025), P13.58B trailing twelve months through March 2026. Net income: P2.43B, P2.89B, P5.03B, P7.32B, P9.54B, P10.05B TTM over the same span. Q1 2026 alone: revenue P3.54B (+21% year on year), net income P2.56B (+25%), EPS P0.69 versus P0.64 a year earlier.

The growth pattern is a REIT doing what REITs are supposed to do: the sponsor (Ayala Land) keeps injecting stabilized, income-producing buildings in exchange for new AREIT shares or cash, and AREIT's income base steps up each time a deal closes. That makes the multi-year revenue chart less like organic same-store growth and more like a series of step-changes layered on top of modest built-in rent escalations (typically low single digits per year on Philippine commercial leases).

Occupancy, lease expiry, and office glut/POGO exposure

AREIT reported 99% overall occupancy as of December 31, 2025, and management has repeatedly said it runs above the broader office market's vacancy rate. In 2023 that meant 93% office occupancy against an industry vacancy rate of 18-20%; management credited the mixed portfolio (offices, malls, hotels, industrial/logistics) for spreading out vacancy risk rather than concentrating it in the most POGO-exposed segment.

Lease expiry looks manageable: as of the 2024 disclosure, fewer than 10% of leases were rolling over in that year, implying a book weighted toward multi-year terms rather than short-dated ones. AREIT does not publish a single blended WALE figure in its press disclosures, so this is inferred from the low annual rollover percentage rather than a stated number.

The offshore gaming (POGO) exit is still a live risk for Philippine office landlords generally. Metro Manila office vacancy sat at 19% in the first quarter of 2026 (down slightly from 19.4% in the fourth quarter of 2025), with POGO-vacated space having made up over half of new vacancies in 2025. Cebu is the sharper flashpoint: office vacancy there hit 17% in mid-2026 with POGO-exit effects still lingering. That matters directly for AREIT because the pending Ayala Land infusions add Cebu office towers (Central Bloc One and Two) and a Cagayan de Oro office building (Centrio Corporate Center) to the portfolio. AREIT's own occupancy has held up so far, but the newly acquired provincial office assets are entering a softer local office market than Metro Manila's, and that is worth watching post-close.

This is the core of the growth story and the main capital-allocation lever available to AREIT (it does not buy third-party buildings; its acquisition pipeline is effectively whatever Ayala Land chooses to inject). Two transactions are in motion in 2026:

A P21 billion property-for-share swap (announced February 2025, priced at P41.50/share) bringing in eight assets across Cebu, Davao, and Cagayan de Oro: Central Bloc One and Two, Ayala Malls Central Bloc, Seda Hotel Central Bloc, Ayala Malls Abreeza, Abreeza Corporate Center, Ayala Malls Centrio, and Centrio Corporate Center.
A P19.5 billion (SEC-approved June 2026) share swap priced at P44.15/share, injecting Ayala Center Cebu and Ayala Malls Feliz in Pasig, adding 441.13 million new shares to be listed.

Together these are described as AREIT's largest annual addition to date, roughly P40.5 billion, and gross leasable area rises to 4.2 million square meters. The P21B deal alone lifts assets under management to about P138 billion; once the P19.5B mall infusion also closes, AUM steps up again to about P158 billion. Management has flagged the new assets carry a blended 6.53% capitalization rate, above AREIT's own trading dividend yield, meaning the deals are accretive to distributable income per share rather than dilutive, at least on the numbers disclosed at announcement. Both deals are expected to close in the second half of 2026. The portfolio mix is shifting toward retail as a result: post-close, retail properties are expected to make up 54% of the building portfolio, up from a heavier office weighting previously, which cuts the REIT's overall office/POGO exposure somewhat even as it adds provincial office towers.

Ayala Land has repeatedly sold down AREIT shares to widen the public float ahead of each infusion, which matters for continued PSEi eligibility and secondary-market liquidity given how much of the register is sponsor-controlled: P4.2 billion in November 2025, then P2.67 billion in June 2026 (75 million shares at P35.60, a 7.5% discount to the prior P38.50 close, the widest discount of any recent AREIT placement versus the roughly 3-4% typical of earlier sales). That widening discount is an early signal the market wants a bigger markdown to absorb the growing share count tied to these infusions.

Distributable income and dividend growth

Philippine REIT law requires AREIT to distribute at least 90% of distributable income (a defined measure that strips out non-cash items like fair value gains, so it is not identical to reported net income). AREIT's FY2025 net income excluding fair value adjustment was about P9.4 billion, close to the P9.54 billion reported net income, so fair value marks were a minor factor in 2025.

The per-share dividend has been on a steady uptrend: P0.42 in June 2021 to P0.62 declared in May 2026, a roughly 10% average annual per-share growth rate over the past three years per third-party trackers. Recent quarterly declarations: P0.58 (March 2025), P0.58 (May 2025), P0.59 (August 2025), P0.62 (November 2025), P0.62 (March 2026), P0.62 (May 2026, ex-date May 26, 2026, paid June 11, 2026). Cash paid to shareholders has scaled with the asset base: P1.73B (2021), P2.91B (2022), P4.07B (2023), P5.82B (2024), P7.92B (2025). The current payout ratio versus trailing EPS is about 83%, comfortably inside the 90%-of-distributable-income mandate given the definitional gap between the two bases. Operating cash flow has grown every year alongside the dividend (P2.21B in 2021 to P9.63B in 2025), so the distributions are backed by real cash generation, not leverage or drawn-down reserves.

ROE and leverage vs the regulatory cap

ROE has improved from 5.96% (2021) to 8.05% currently, with ROA up from 3.27% to 4.61% and ROIC from 5.47% to 7.18% over the same stretch. These are modest by non-REIT standards, which is normal: REITs are asset-heavy vehicles that retain very little of their earnings (the 90% payout rule keeps equity growing mainly through fresh share issuances tied to each infusion, not retained profit), so ROE tracks the quality of newly injected assets more than it tracks operating leverage.

Debt is close to nonexistent: D/E of 0.03 and Debt/EBITDA of 0.35, both down sharply from 2021 levels (D/E 0.10, Debt/EBITDA 2.11). Philippine REIT law caps total borrowings at 35% of deposited property value, extendable to 70% for REITs with a public investment-grade credit rating. AREIT is running far below either threshold, which means it has substantial capacity to fund future sponsor infusions with debt rather than always issuing new shares, a lever it has barely used so far. That headroom is a genuine strength: it gives AREIT room to keep growing without diluting existing holders every time, though management has so far preferred equity-funded (share swap) infusions for the two 2026 deals.

Capital allocation

AREIT's capital allocation is almost entirely a function of the sponsor relationship: accept accretive property injections from Ayala Land in exchange for shares (occasionally cash), pay out at least 90% of distributable income as dividends, and keep debt low. There is no meaningful third-party acquisition activity, no buybacks, and no diversification bets outside real estate, by REIT design. The main judgment call for an outside investor is whether to trust that Ayala Land, as both sponsor and majority shareholder, will keep pricing these infusions fairly (cap rate above trading yield, as claimed for the 2026 deals) rather than using AREIT as a vehicle to offload weaker assets or dilute minority holders over time. Nothing in the disclosed terms so far suggests the latter, but it is the structural risk worth monitoring in every future related-party transaction.

Verdict at P37.25 (July 19, 2026)

Buy, for investors who want steady, growing Philippine peso income and are comfortable owning a name whose growth engine is a related-party pipeline rather than pure organic leasing. This is a quiet week: the price drifted down slightly from P37.40 (July 12) to P37.25 (July 17 close), staying inside the same P37.00-P37.40 band it has held for the past eight trading sessions. No new dividend has been declared since the P0.62 quarterly in May 2026 (the next declaration is not due yet on the established quarterly cadence), no Q2 2026 earnings have been released, and neither of the two pending Ayala Land infusions (P21B, P19.5B) has confirmed closing despite both being "targeted" for the second half of 2026. The fundamentals are unchanged from the last review: 99% occupancy against a Metro Manila office market still running about 19% vacant, near-zero debt against a 35%/70% regulatory ceiling, a dividend that has grown roughly 10% a year, and a P/B of about 1.02. Trailing P/E of about 13.3x and a 6.66% yield are reasonable, not screaming cheap, for an asset with this occupancy quality and growth track record.

Neither buy trigger nor sell trigger has fired. The two live risks are unchanged: the office/POGO overhang on the newly acquired provincial towers (Cebu vacancy at 17% is worse than Metro Manila's) and the standing question of whether Ayala Land will always price future infusions fairly to minority shareholders. The June 2026 share placement at a 7.5% discount, the widest of any recent AREIT block sale, remains the data point worth watching for a repeat or a widening trend once the pending infusions actually close.

What would change the call:

Buy trigger: price weakness pushes the yield toward 7.5-8% while occupancy holds in the high 90s and a pending infusion still prices above the trading yield (confirms continued accretion at a better entry).
Sell trigger: occupancy in the office segment (especially the newly acquired Cebu/Davao/CDO towers) drops into the mid-to-high 80s as POGO-vacated space goes unabsorbed, or a future sponsor infusion is priced at a cap rate below AREIT's trading yield (value-destructive to existing holders), or debt is drawn toward the regulatory cap without a matching, disclosed increase in distributable income.

Analysis, not financial advice.

Committee review (July 19, 2026)

Five investor lenses judged this page's facts independently, each confined to its own framework:

Lens	Signal	Confidence	Core argument
Ben Graham	Neutral	55	Graham demands roughly a decade of demonstrated earnings stability, including a downturn survived, before certifying safety; AREIT has only 5-6 years since its 2020 IPO and has never been tested by a real estate downcycle, even though the balance sheet is genuinely conservative (D/E 0.03, Debt/EBITDA 0.35, far under the 35% cap). P/E 13.31x and P/B 1.02 offer modest margin of safety on assets, but the 83% payout leaves no retained buffer, and growth depends on sponsor-injected share issuance rather than organic earnings Graham could underwrite.
Warren Buffett	Bullish	62	99% occupancy against a ~19% Metro Manila vacancy market signals a genuine moat: irreplaceable, diversified assets sponsor-fed at a claimed 6.53% cap rate above trading yield. Debt/EBITDA of 0.35 (down from 2.11) and D/E of 0.03 show a fortress balance sheet, and ROE climbing from 5.96% to 8.05% with growing operating cash flow (P2.21B to P9.63B) reflects real, compounding owner earnings. The one blemish: repeated sponsor share sales at widening discounts (7.5% in June 2026) raise a management-alignment question worth watching, not yet worth abandoning the thesis.
Michael Burry	Bearish	75	A 1.02 P/B provides no real margin of safety once you strip out sponsor-priced infusions. ROE of just 8.05% and equity growth driven by new share issuance (not retained earnings) mean book value reflects Ayala Land's own fairness opinions, not organic cash generation. The claimed 6.53% blended cap rate on the pending P21B and P19.5B deals cannot be checked against independent comps, and Ayala Land selling shares at a 7.5% discount right before asking the market to absorb more sponsor assets is the tell: insiders aren't buying their own marks. Add 19% Metro Manila vacancy, worsening Cebu, no dividend since May, and no Q2 print, and the accounting narrative outruns the cash reality.
Nassim Taleb	Bearish	65	Balance-sheet fragility is genuinely absent (D/E 0.03, Debt/EBITDA 0.35), but that is not where the risk sits. AREIT has zero optionality over what it buys; sponsor-priced fairness opinions decide the terms, and Ayala Land keeps selling down its stake (P4.2B, then P2.67B at a 7.5% discount) right before every injection, skin in the game inverted. Minority holders absorb undiversified tail risk in Cebu/Davao/CDO towers sitting in a 17-19% vacant market: capped upside as a yield stock, open-ended downside from concentration into a soft, unproven market.
Stanley Druckenmiller	Neutral	60	Two live catalysts exist (Ayala Land infusions at P41.50/P44.15, both above the P37.25 print) but neither is confirmed, just "targeted" for H2, so there is nothing to front-run yet. The macro backdrop actively fights the trade: 19% Manila vacancy and worsening 17% Cebu vacancy sit directly under the Cebu/Davao/CDO towers being injected, and the widened 7.5% discount on the last placement signals the market already doubts the premium pricing holds. Eight days of flat P37.00-P37.40 tape confirms no one is positioning either way.

Conferred call: Hold (1 bullish, 2 bearish, 2 neutral, no majority either way, unchanged from the July 12, 2026 committee run). This disagrees with the page's Buy recommendation: the Recommendation is built for a multi-year income holder who can look through the growing-pains supply overhang, while the committee is more split on the interim risk that the same overhang creates a near-term price drag. Both stand; the disagreement is the information. Checked against [[stock-trading-strategy-and-rules]]: the rulebook's warning against buying purely because a stock sits near a 52-week low applies loosely here (P37.25 is close to the P36.10 low of the 52-week range), and the lack of a confirmed near-term catalyst (echoed by Burry, Taleb, and Druckenmiller) argues for patience over urgency on any new buying, even though the page's long-term income thesis is intact.

Shared flip trigger: several lenses (Burry, Taleb, Druckenmiller) converge on the same tell: if the next sponsor share placement clears at a discount wider than June's 7.5%, or a future infusion prices below AREIT's trading yield, treat it as confirmation the sponsor pipeline is turning value-destructive to minority holders.

Review history

Date	Price	Recommendation
July 10, 2026	37.35	Buy (income and dividend-growth investors)
July 12, 2026	37.40	Buy (income and dividend-growth investors); committee conferred Hold
July 19, 2026	37.25	Buy (income and dividend-growth investors); committee conferred Hold